Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Data and Long-term FU of Pre-/Perimenopausal Women With Luminal EBC With Intermediate to High Clinical and Low Genomic Recurrence-risk Measured by MammaPrint®, Treated by SOC ET+OFS or SOC Chemotherapy Treatment Followed by ET

NCT05792150 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.

NCT NCT05792150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05792150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Data and Long-term FU of Pre-/Perimenopausal Women With Luminal EBC With Intermediate to High Clinical and Low Genomic Recurrence-risk Measured by MammaPrint®, Treated by SOC ET+OFS or SOC Chemotherapy Treatment Followed by ET
Lead sponsor
Women's Cancer Study Group GmbH
Phase
Observational
Overall status
Recruiting
Start date
December 7, 2022
Completion date
June 30, 2035
Enrollment
1,470 (estimated)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

female breast cancer